Results 11 to 20 of about 1,809 (187)

Evolving TRALI risk across apheresis and whole blood platelet products in the United States: An 18-year American Red Cross hemovigilance analysis. [PDF]

open access: yesTransfusion
Transfusion‐related acute lung injury (TRALI) remains a leading cause of transfusion‐associated mortality in the United States. Donor‐based mitigation has reduced TRALI risk from plasma and apheresis platelets, but the residual risk associated with whole‐
Young PP, Singh U, Webb J, Looney MR.
europepmc   +3 more sources

An Integrated Review of Pharmacovigilance, Materiovigilance, and Hemovigilance Programs in India: Evolution, Implementation, and Impact on Patient Safety [PDF]

open access: yesBatna Journal of Medical Sciences
The drug development process is complex, with a central focus on ensuring quality, safety, and efficacy. Despite rigorous clinical trials, adverse drug reactions (ADRs) often become apparent only after widespread clinical use, making post-marketing ...
Venkata Naveen kumar PARUCHURI   +5 more
doaj   +2 more sources

The impact of hemovigilance studies on transfusion practices: Single centre experience

open access: yesHitit Medical Journal
Objective: Blood product transfusion is one of the most commonly used medical interventions worldwide. However, transfusion-related adverse events (TRAEs) can cause morbidity and rarely even mortality.
Samet Yaman   +5 more
doaj   +2 more sources

Novel method for trend change detection and hypothesis generation in hemovigilance: A transfusion-related immunomodulation and blood production changes study.

open access: yesTransfusion, EarlyView.
BACKGROUND Immunomodulatory consequences of transfusion, known as transfusion-related immune modulation (TRIM), impact patients but are not captured by hemovigilance systems. This study's objective is to explore TRIM impacts of production changes made by
S. Ning   +15 more
semanticscholar   +2 more sources

Adverse transfusion reactions following transfusion of blood and blood products in a tertiary care hospital: A step toward hemovigilance

open access: yesAsian Journal of Medical Sciences
Background: Transfusion of blood and blood products is a double-edged sword, so it should be used judiciously. The primary aim of the centralized hemovigilance program is to improve transfusion safety.
Mrigen Choudhury   +3 more
doaj   +2 more sources

Blood transfusion reactions and institutional hemovigilance protocols: A 2-year retrospective single center audit

open access: yesInternational Journal of Medicine and Health Development, 2023
Background: Blood transfusion reactions contribute significantly to the morbidity and mortality of both in- and outpatients in hospitals globally. Developing adequate protocols for detecting and reporting this complication is key to attaining global ...
John C Aneke   +8 more
doaj   +2 more sources

Hemovigilance and blood safety

open access: yesAsian Journal of Transfusion Science, 2012
Ashish Jain, Ravneet Kaur
doaj   +3 more sources

Clinical evaluation of novel blood collection and storage bags containing alternative plasticizers to DEHP: Recommendations from the BEST collaborative. [PDF]

open access: yesTransfusion
Transfusion, Volume 65, Issue 12, Page 2414-2422, December 2025.
Brown B   +6 more
europepmc   +2 more sources

Implementing bedside electronic transfusion checks at Barts Health NHS Trust: A study protocol for evaluating the effectiveness and value for money. [PDF]

open access: yesTransfus Med
Abstract Objective To evaluate the benefits of implementing Bedside Electronic Transfusion Checks (BETC) to patients and value for money at four hospitals at Barts Health NHS Trust. Background BETC aims to enhance transfusion safety by reducing errors associated with positive patient identification checks for compatibility, blood sample labelling, and ...
Ahmed M   +12 more
europepmc   +2 more sources

Safety and contribution of elderly whole blood donors after raising the upper age limit: Hemovigilance data from a Chinese region from 2012 to 2023. [PDF]

open access: yesPLoS One
Background In 2012, China raised the upper age restriction for blood donors from 55 to 60 years old. This study analyzed the impact of raising the upper age restriction on whole blood donor health, contribution to blood supply, and safety of blood ...
Yang C, Jiang X, Ren Y, Zhu X, Yang J.
europepmc   +2 more sources

Home - About - Disclaimer - Privacy